Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | ICMT | O60725 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR1B | P28222 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809336 | 0.92 | ICMT (0.38) | KDRICMTHTR1AHTR1BDRD4 | |
| SCHEMBL23809476 | 0.91 | ICMT (0.41) | KDRICMTCNR2HTR1AHTR1B | |
| SCHEMBL26581577 | 0.85 | ICMT (0.41) | KDRICMTCNR2HTR1AHTR1B | |
| SCHEMBL20604957 | 0.82 | KDR (0.39) | KDRICMTCNR2HTR1AHTR1B | |
| SCHEMBL23809421 | 0.81 | DYRK1A (0.40) | CNR2CNR1MCL1 | |
| SCHEMBL23809237 | 0.78 | DRD2 (0.43) | ICMTHTR1AHTR1BDRD4DRD3 | |
| SCHEMBL23809246 | 0.78 | MEN1 (0.43) | — | |
| SCHEMBL23809414 | 0.78 | HTR1A (0.42) | ICMTCNR2HTR1AHTR1BDRD4 | |
| SCHEMBL23809277 | 0.77 | SLC22A12 (0.47) | CNR2CNR1KDM4E | |
| SCHEMBL26581580 | 0.77 | ICMT (0.42) | KDRICMTHTR1AHTR1BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDR 2913/4885ICMT 4607/4885CNR2 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.